[go: up one dir, main page]

MX2010001218A - Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos. - Google Patents

Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.

Info

Publication number
MX2010001218A
MX2010001218A MX2010001218A MX2010001218A MX2010001218A MX 2010001218 A MX2010001218 A MX 2010001218A MX 2010001218 A MX2010001218 A MX 2010001218A MX 2010001218 A MX2010001218 A MX 2010001218A MX 2010001218 A MX2010001218 A MX 2010001218A
Authority
MX
Mexico
Prior art keywords
methods
compositions
combination therapy
treating schizophrenia
antipsychotic
Prior art date
Application number
MX2010001218A
Other languages
English (en)
Inventor
Sergey Olegovich Bachurin
Vladimir Viktorovich Grigoriev
Margarita A Morozova
Allan G Beniashvili
Original Assignee
Medivation Neurology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2007129567/15A external-priority patent/RU2508106C2/ru
Priority claimed from RU2007129568/15A external-priority patent/RU2508096C2/ru
Application filed by Medivation Neurology Inc filed Critical Medivation Neurology Inc
Publication of MX2010001218A publication Critical patent/MX2010001218A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invenci?n se relaciona con terapias combinadas y m?todo para el tratamiento, prevenci?n y/o retraso del inicio y/o el desarrollo de esquizofrenia, donde las terapias combinadas comprenden pirido (4,3-b) indol hodrogeando o una sal farmac?uticamente aceptable de lo mismo, como dimebon, y un agente antipsic?tico.
MX2010001218A 2007-08-01 2008-08-01 Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos. MX2010001218A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2007129567/15A RU2508106C2 (ru) 2007-08-01 2007-08-01 Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
RU2007129568/15A RU2508096C2 (ru) 2007-08-01 2007-08-01 Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
PCT/US2008/009357 WO2009017836A1 (en) 2007-08-01 2008-08-01 Methods and compositions for treating schizophrenia using antipsychotic combination therapy

Publications (1)

Publication Number Publication Date
MX2010001218A true MX2010001218A (es) 2010-04-07

Family

ID=40304696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001218A MX2010001218A (es) 2007-08-01 2008-08-01 Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.

Country Status (10)

Country Link
US (1) US20110269777A1 (es)
EP (1) EP2175724A4 (es)
JP (1) JP2010535220A (es)
KR (1) KR20100054812A (es)
CN (1) CN101842010A (es)
AU (1) AU2008282742A1 (es)
BR (1) BRPI0815850A2 (es)
CA (1) CA2719824A1 (es)
MX (1) MX2010001218A (es)
WO (1) WO2009017836A1 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7837812B2 (en) 2004-05-21 2010-11-23 Ati Properties, Inc. Metastable beta-titanium alloys and methods of processing the same by direct aging
CN101868234A (zh) 2007-09-20 2010-10-20 D2E有限公司 具有神经保护和认知增强特性的氢化吡啶并[4,3-b]吲哚的含氟衍生物,其制备方法及应用
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2280968A2 (en) 2008-03-24 2011-02-09 Medivation Technologies, Inc. Pyrido [3, 4-b]indoles and methods of use
JP5586577B2 (ja) 2008-03-24 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 架橋複素環化合物およびその使用
AU2009251816B2 (en) 2008-05-27 2015-12-10 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
CN102271508B (zh) 2008-10-31 2015-04-29 梅迪维新技术公司 含有刚性部分的吡啶并[4，3-b]吲哚类化合物
CA2742322A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Azepino[4,5-b]indoles and methods of use
WO2010093425A1 (en) 2009-02-11 2010-08-19 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2581374B1 (en) * 2009-04-10 2014-03-19 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Preparation of tetrahydropyrido[4,3-b]indole derivatives
US9255094B2 (en) 2009-04-29 2016-02-09 Medivation Technologies, Inc. Pyrido[4,3-B]indoles and methods of use
JP5827943B2 (ja) 2009-04-29 2015-12-02 メディベイション テクノロジーズ， インコーポレイテッド ピリド［４，３−ｂ］インドールおよびその使用方法
WO2011038164A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
CN102724875B (zh) 2009-09-23 2015-05-27 梅迪维新技术公司 吡啶并[3,4-b]吲哚化合物及其使用方法
EP2480078A4 (en) 2009-09-23 2013-03-06 Medivation Technologies Inc PYRIDO- [4,3-B] INDOLE AND USE METHOD THEREFOR
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103485A1 (en) * 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103448A1 (en) * 2010-02-19 2011-08-25 Medivation Technologies, Inc. Methods and compositions for treating psychotic disorders using antipsychotic combination therapy
WO2011106536A2 (en) 2010-02-24 2011-09-01 The Broad Institute, Inc Methods of diagnosing infectious disease pathogens and their drug sensitivity
AU2012219251B2 (en) 2011-02-18 2016-05-12 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US20140303144A1 (en) 2011-02-18 2014-10-09 Medivation Technologies, Inc. Compounds and methods of treating hypertension
US9199985B2 (en) 2011-02-18 2015-12-01 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
AU2013245702A1 (en) 2012-04-14 2014-11-13 Intra-Cellular Therapies, Inc. Organic compounds
JPWO2014128882A1 (ja) * 2013-02-21 2017-02-02 医療法人 和楽会 不安うつ病の治療薬
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2015085004A1 (en) 2013-12-03 2015-06-11 Intra-Cellular Therapies, Inc. Novel methods
KR20170012210A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
KR101646962B1 (ko) 2014-09-29 2016-08-10 한국과학기술연구원 CaM 저해활성을 가지는 페노싸이아진 유도체
US20160184290A1 (en) * 2014-12-31 2016-06-30 Paul J. Markovitz Method of treating schizophrenia
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
WO2016205631A1 (en) * 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規塩類および結晶
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11331316B2 (en) * 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562486B1 (en) 2016-12-31 2024-03-13 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
WO2018175969A1 (en) 2017-03-24 2018-09-27 Intra-Cellular Therapies, Inc. Novel compositions and methods
US10035795B1 (en) 2017-04-06 2018-07-31 Korea Institute Of Science And Technology Phenothiazine derivatives having CaM inhibitory activity
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CA3071137A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Prodrugs of substituted heterocycle fused gamma-carbolines
CN111093665A (zh) 2017-07-26 2020-05-01 细胞内治疗公司 有机化合物
JP2020535231A (ja) 2017-09-26 2020-12-03 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規な塩および結晶
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
WO2019183341A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
MX2020013116A (es) 2018-06-06 2021-05-12 Intra Cellular Therapies Inc Sales y cristales novedosos.
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP3813802B1 (en) 2018-06-27 2024-10-23 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
JP7546546B2 (ja) 2018-08-31 2024-09-06 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
AU2019331490B2 (en) 2018-08-31 2025-04-24 Intra-Cellular Therapies, Inc. Novel methods
WO2020132474A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compound
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
AU2020316013A1 (en) 2019-07-19 2022-02-17 Arx, Llc Non-sedating dexmedetomidine treatment regimens
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP4297871A4 (en) * 2021-02-26 2025-01-01 BioXcel Therapeutics, Inc. METHODS AND COMPOSITIONS FOR TREATING AGITATION
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
CN115290775A (zh) * 2022-07-25 2022-11-04 上海市徐汇区中心医院 一种精神类药物质控品、其试剂盒、制备方法及应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229067B1 (en) * 1981-08-20 1984-04-16 Svorad Stolc Medicinal preparation with antiarhythmic and supporting effect applied with hypoxia,and method of preparing active substance thereof
US4672117A (en) * 1985-09-16 1987-06-09 American Home Products Corporation Antipsychotic gamma-carbolines
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
US5631265A (en) * 1994-03-11 1997-05-20 Eli Lilly And Company 8-substituted tetrahydro-beta-carbolines
RU2140417C1 (ru) * 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
TW470745B (en) * 1996-05-23 2002-01-01 Janssen Pharmaceutica Nv Hexahydro-pyrido[4,3-b]indole derivatives
WO2003014118A1 (en) * 2001-08-08 2003-02-20 Pharmacia & Upjohn Company THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES
WO2005120463A1 (en) * 2004-06-09 2005-12-22 Ranbaxy Laboratories Limited Rapidly disintegrating tablets of risperidone
EP1937263A2 (en) * 2005-10-04 2008-07-02 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
JP2009513672A (ja) * 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
RU2338537C2 (ru) * 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
KR20100024951A (ko) * 2007-05-25 2010-03-08 메디베이션 뉴롤로지 인코퍼레이티드 세포를 자극하기 위한 방법 및 조성물

Also Published As

Publication number Publication date
CN101842010A (zh) 2010-09-22
JP2010535220A (ja) 2010-11-18
WO2009017836A1 (en) 2009-02-05
BRPI0815850A2 (pt) 2014-10-07
US20110269777A1 (en) 2011-11-03
EP2175724A1 (en) 2010-04-21
AU2008282742A1 (en) 2009-02-05
KR20100054812A (ko) 2010-05-25
EP2175724A4 (en) 2010-09-15
CA2719824A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
MX2009004516A (es) Metodos y terapias de combinacion para tratar enfermedad de alzheimer.
UA100400C2 (uk) Похідні спіроциклічних амідів
WO2011103460A8 (en) Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
UA99459C2 (en) 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2009120717A3 (en) Pyrido [3, 4-b] indoles and methods of use
WO2011019417A8 (en) Pyrido [4, 3-b] indoles and methods of use
WO2009094668A8 (en) New 2,3,4,5-tetrahydro-1h-pyrido[ 4,3-b] indole compounds and methods of use thereof
WO2010127177A8 (en) Pyrido [4,3-b] indoles and methods of use
WO2008036410A3 (en) Methods and compositions for treating amyotrophic lateral sclerosis (als)
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
MY148583A (en) Pyridine [3,4-b] pyrazinones
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
MY158257A (en) Forms of rifaximin and uses thereof
MX2009012595A (es) Derivados de espiroindolinona.
IL187382A0 (en) Bicyclic derivatives as modulators of ion channels
WO2010002956A3 (en) Heterocyclic derivatives as modulators of ion channels
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
SG170033A1 (en) Octahydro-pyrrolo[3,4-b] pyrrole derivatives and their use as histamine-3 receptor ligands
MX2010008717A (es) (dihidro) pirrolo [2,1-a] isoquinolinas.
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal